Longtime Seattle Genetics COO Jumps Ship to Helm Biotech Startup Silverback Therapeutics Post author:Sam Post published:December 3, 2017 Post category:BioPharma The COO of Seattle Genetics, Eric Dobmeier, is leaving the company to helm Silverback Therapeutics. Source: BioSpace You Might Also Like BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program January 29, 2018 Bio-Rad to Shut Down Cambridge R&D Site in Consolidation October 8, 2017 Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs March 7, 2018
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program January 29, 2018